Unknown

Dataset Information

0

In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

ABSTRACT: Duchenne muscular dystrophy (DMD) is a devastating disease affecting about 1 out of 5000 male births and caused by mutations in the dystrophin gene. Genome editing has the potential to restore expression of a modified dystrophin gene from the native locus to modulate disease progression. In this study, adeno-associated virus was used to deliver the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system to the mdx mouse model of DMD to remove the mutated exon 23 from the dystrophin gene. This includes local and systemic delivery to adult mice and systemic delivery to neonatal mice. Exon 23 deletion by CRISPR-Cas9 resulted in expression of the modified dystrophin gene, partial recovery of functional dystrophin protein in skeletal myofibers and cardiac muscle, improvement of muscle biochemistry, and significant enhancement of muscle force. This work establishes CRISPR-Cas9-based genome editing as a potential therapy to treat DMD.

SUBMITTER: Nelson CE 

PROVIDER: S-EPMC4883596 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Duchenne muscular dystrophy (DMD) is a devastating disease affecting about 1 out of 5000 male births and caused by mutations in the dystrophin gene. Genome editing has the potential to restore expression of a modified dystrophin gene from the native locus to modulate disease progression. In this study, adeno-associated virus was used to deliver the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system to the mdx mouse model of DMD to remove the mutated exon 23 from the d  ...[more]

Similar Datasets

Unknown In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
| S-EPMC8042958 | biostudies-literature
Unknown PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.
| S-EPMC7791088 | biostudies-literature
Other In vivo genome editing restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers
2021-03-01 | GSE168007 | GEO
Other In vivo genome editing restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers [WES]
2021-02-28 | GSE167586 | GEO
Unknown Pharmacological TRPC6 inhibition improves survival and muscle function in mice with Duchenne muscular dystrophy.
| S-EPMC9675567 | biostudies-literature
Transcriptomics In vivo genome editing restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers [RNA-seq]
2021-02-28 | GSE167585 | GEO
Other In vivo genome editing restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers [GUIDE-seq]
2021-02-28 | GSE167583 | GEO
Other In vivo genome editing restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers [Amplicon-seq]
2021-02-28 | GSE167572 | GEO
Other In vivo genome editing restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers [Nanopore sequencing]
2021-02-28 | GSE167584 | GEO
Unknown VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy.
| S-EPMC8055526 | biostudies-literature